Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform-independent assays, in concert with genetic, epidemiological, translational, and pathophysiological insights, have established Lp(a) as an independent, genetic, and likely causal risk factor for CVD and CAVS. These observations are consistent across a broad spectrum of patients, risk factors, and concomitant therapies, including patients with low-density lipoprotein cholesterol <70 mg/dl. Statins tend to increase Lp(a) levels, possibly contributing to the "residual risk" noted in outcomes trials and at the bedside. Recently approved proprotein convertase subtilisin/kexin-type 9 inhibitors and mipomersen lower Lp(a) 20% to 30%, and emerging RNA-targeted therapies lower Lp(a) >80%. These approaches will allow testing of the "Lp(a) hypothesis" in clinical trials. This review summarizes the current landscape of Lp(a), discusses controversies, and reviews emerging therapies to reduce plasma Lp(a) were abrogated by inactivating OxPL with a specific antibody or using recombinant apo(a) constructs lacking OxPL, which suggested that these effects In meta-analyses of clinical outcomes, the risk of Lp(a) for CVD is curvilinear (25). In contrast, genetic studies, which reflect life-long elevated Lp(a) and less confounding by the multiple heterogeneous limitations in meta-analyses, show a more potent and linear risk, with odds ratios as high as 4 relative to subjects with low levels (27,30). Figure 4 represents the salient studies that show such asso- analyzed, the LPA SNP rs10455872, which is associated with markedly elevated Lp(a) levels, was the only monogenetic risk factor for aortic valve calcification and CAVS in multiple racial groups (34-37).
Plasminogen is a proenzyme, which is converted to the fibrinolytic enzyme plasmin by plasminogen activators, such as urokinase and tissue plasminogen activator, either endogenously or iatrogenically.
Apo(a) does not contain KI to KIII of plasminogen, but instead contains 10 subtypes of KIV (with KIV 1 and KIV 3-10 present in 1 copy, and KIV 2 present in 1 to >40 copies), 1 copy of KV, and an inactive protease domain. Unlike apoB, apo(a) does not contain lipid domains or transport lipid, but instead, it is hydrophilic, and can bind to denuded and exposed lysinerich vascular endothelium, similar to and also in competition with plasminogen. However, except for high Lp(a) levels, on a molar basis, plasminogen is almost always in excess of apo(a), which calls into question its in vivo potency in inhibiting plasminogen activity in most patients.
Within populations, there is extensive apo(a) protein size heterogeneity, with >40 different isoforms, and thus, >40 different sizes of Lp(a) particles, which is a unique occurrence unlike other circulating proteins, which usually have 1 defined mass (5) . Within individuals, >80% carry 2 different-sized apo(a) isoforms, each inherited from 1 parent. For example, an individual may carry 2 small isoforms, a small and a large one, or 2 large isoforms, with plasma Lp(a) levels determined by the net production of apo(a) in each isoform, with the major contribution generally driven by the small isoform ( Figure 1 ).
METABOLISM OF Lp(a)
Circulating Lp(a) levels are primarily determined by the LPA gene locus, without significant dietary or environmental influences (6) . Apo(a) is synthesized almost exclusively in the liver, but the site of assembly of Lp(a) has not been confirmed, and may be within the hepatocyte, the space of Disse, or the plasma compartment (7) . The steps of assembly include apo(a) docking to LDL, and then formation of a covalent disulfide bond between KIV-9 of apo(a) and apoB of LDL. It appears that the LDL component is derived from a newly synthesized apoB-100 and is not derived from a very low-density lipo- Lipoprotein(a) Lipoprotein [Lp(a)] is composed of apolipoprotein B-100 (apoB-100) covalently bound to apolipoprotein (a) [apo(a)], which is derived from kringle IV (KIV) and KV, and the protease domain of plasminogen. Plasminogen has 1 copy each of KI to KV and an active protease domain. Apo(a) contains 10 subtypes of KIV repeats, composed of 1 copy each of KIV 1 , multiple copies of KIV 2 , and 1 copy of KIV 3À10 , KV, and an inactive protease-like (P) domain. In these examples, apo(a) isoforms of 4, 8, 24 , and 40 KIV 2 repeats are shown, representing 13, 17, 33, and 49 total KIV repeats. Oxidized phospholipids (OxPL), represented here by 1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphocholine (POVPC), are present covalently bound to apo(a), and also dissolved in the lipid phase of apoB-100. Tsimikas JACC VOL. 69, NO. 6, 2017 Lipoprotein(a) F E B R U A R Y 1 4 , 2 0 1 7 : 6 9 2 -7 1 1 through its content of oxidized phospholipids (OxPL), the presence of lysine binding sites that allow accumulation in the arterial wall, and potential antifibrinolytic effects by inhibiting plasminogen activation ( Figure 2 ) (reviewed in Spence and Koschinsky [9] ). However, Lp(a)-mediated CVD risk should be considered in a quantitative manner because most patients (70% to 80%) at risk for CVD have low Lp(a) levels, such that LDL-C is present in significant excess to Lp(a), and therefore, most of the apoB-driven risk is due to a higher number of LDL particles. However, as Lp(a) levels increase to >25 to 30 mg/dl, which represents w30% of the population, the risk of Lp(a) rises in a linear fashion according to absolute circulating Lp(a) mass.
The OxPL components of Lp(a), which can be present in the lipid phase of Lp(a) and also be covalently bound to apo(a) (10) (11) (12) , are proinflammatory and impart many of the proatherogenic properties of Lp(a) (Figure 2) . This has been shown in clinical studies by measuring levels of OxPL on apoB-containing particles (OxPL-apoB), which primarily reflect the OxPL content of Lp(a) (10, 11) , which demonstrates that elevated OxPL-apoB levels are either similar or superior predictors to Lp(a) in the diagnosis or prognosis of CVD (13) (14) (15) (16) (17) (18) and CAVS (19, 20) . In a recent study that validated these mechanisms in vivo, patients with elevated Lp(a) had increased arterial inflammation detected by increased accumulation of 18-fluorodeoxyglucose in the carotid arteries and aorta. In addition, their monocytes demonstrated increased production of proinflammatory cytokines upon stimulation and an enhanced capacity to transmigrate in an in vitro system, which reflected vascular penetration of monocytes through an endothelial cell barrier. These proinflammatory effects were associated with enhanced in vivo monocyte trafficking to the arterial wall using autologous radiolabeled monocytes, and were abrogated by inactivating OxPL with a specific antibody or using recombinant apo(a) constructs lacking OxPL, which suggested that these effects The atherogenicity of Lp(a) can be broadly classified in 3 categories: proatherogenic, proinflammatory, and potentially antifibrinolytic. The major individual mechanisms within each category are listed. EC ¼ endothelial cell; IL ¼ interleukin; MCP ¼ monocyte chemoattractant protein; PAI ¼ plasminogen activator inhibitor; SMC ¼ smooth muscle cell; TFPI ¼ tissue factor pathway inhibitor; other abbreviation as in Figure 1 .
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Lipoprotein(a) In meta-analyses of clinical outcomes, the risk of Lp(a) for CVD is curvilinear (25) . In contrast, genetic studies, which reflect life-long elevated Lp(a) and less confounding by the multiple heterogeneous limitations in meta-analyses, show a more potent and linear risk, with odds ratios as high as 4 relative to subjects with low levels (27,30). Figure 4 represents the salient studies that show such asso- analyzed, the LPA SNP rs10455872, which is associated with markedly elevated Lp(a) levels, was the only monogenetic risk factor for aortic valve calcification and CAVS in multiple racial groups (34) (35) (36) (37) .
Similar to the studies with myocardial infarction, a Although genetic and epidemiological data strongly support the prognostic causality of Lp(a), the Lipoprotein(a) 
AREA OF CONTROVERSY V: IS THERE A DIFFERENCE IN Lp(a)-MEDIATED CVD RISK IN DIFFERENT RACIAL GROUPS?
It is well appreciated that racial differences exist in Lp(a) levels, apo(a) isoforms, and LPA SNPs Lipoprotein(a) CHD ¼ coronary heart disease; other abbreviations as in Figures 1 and 4 . 
AREA OF CONTROVERSY VII: DO STATINS INCREASE Lp(a) LEVELS?
The knowledge on the effect of statins on Lp(a) is evolving. It has been believed that statins do not affect Lp(a) levels because the LDLR is thought to play either no role or a minor role in Lp(a) clearance.
Although definitive data do not currently exist, a close assessment of published reports has suggested that statins tend to raise Lp(a) by 10% to 20%, particularly when the data are evaluated as pre-and post-statin levels in individual patients rather than mean levels in groups. For example, in a recent analysis of 3,896 patients in whom Lp(a) and OxPLapoB were measured pre-and post-statin therapy, including atorvastatin, pravastatin, rosuvastatin, pitavastatin, and simvastatin/ezetimibe, the mean patient-level Lp(a) increased by 11% (and up to 50% in some studies), and OxPL-apoB increased by 24% ( Figure 9 ) (60). This might also explain why some patients do not respond well to LDL-C lowering by statins, because most of their cholesterol is on Lp(a), rather than LDL particles (61) , and Lp(a) can increase with statin therapy. This should be a clue to physicians that lack of response to statin therapy could be Hazard Ratio (95% CI) for CV Events
This forest plot shows a study-level analysis of baseline low-density lipoprotein cholesterol (LDL-C) levels and Lp(a) levels greater than the fourth quartile and the associated hazard ratio compared with the lowest quartile. For AIM-HIGH, quartile 3 was >33.8 to 125.2 nmol/l and quartile 4 was >125.2 nmol/l; quartiles 1 and 2 were not given. For LIPID, quartile 1 was #13.9 mg/dl, quartile 2 was 13.9 to 44.1 mg/dl, quartile 3 was 44.1 to 73.7 mg/dl, and quartile 4 was >73.7 mg/dl. For JUPITER, However, this analysis was underpowered, with only w700 patients and an event rate of w16%. Because only apo(a) is targeted, the liver can continue to make very low-density lipoprotein and LDL, and export them to the circulation. Antisense oligonucleotide (ASO) to apo(a) inhibits both alleles of apo(a). Abbreviations as in Figures 1 and 3 . Initial studies suggested that mipomersen, an ASO that inhibited apoB mRNA, could lower Lp(a) and OxPL-apoB in transgenic Lp(a) (75) . Interestingly, the mechanism was a marked reduction of apoB production, such that apoB was limiting Lp(a) assembly.
Mipomersen did not affect production of apo(a), which continued to be secreted into the circulation as Lipoprotein(a)
